Role of Bisphosphonates in Prostate Cancer Bone Metastases

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.

Original languageEnglish (US)
Pages (from-to)717-723
Number of pages7
JournalSeminars in Oncology
Volume30
Issue number5
DOIs
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Bone Neoplasms
Diphosphonates
Prostatic Neoplasms
Bone Density Conservation Agents
Neoplasm Metastasis
Tumor Burden
Androgens
Animal Models
Quality of Life
Clinical Trials
Costs and Cost Analysis
Bone and Bones
Pain
Survival
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology

Cite this

Role of Bisphosphonates in Prostate Cancer Bone Metastases. / Guise, Theresa; Chirgwin, John.

In: Seminars in Oncology, Vol. 30, No. 5, 10.2003, p. 717-723.

Research output: Contribution to journalArticle

@article{1140e8853cbc4632ac2f04afb5f6995b,
title = "Role of Bisphosphonates in Prostate Cancer Bone Metastases",
abstract = "Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.",
author = "Theresa Guise and John Chirgwin",
year = "2003",
month = "10",
doi = "10.1016/S0093-7754(03)00347-6",
language = "English (US)",
volume = "30",
pages = "717--723",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Role of Bisphosphonates in Prostate Cancer Bone Metastases

AU - Guise, Theresa

AU - Chirgwin, John

PY - 2003/10

Y1 - 2003/10

N2 - Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.

AB - Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=0142030701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142030701&partnerID=8YFLogxK

U2 - 10.1016/S0093-7754(03)00347-6

DO - 10.1016/S0093-7754(03)00347-6

M3 - Article

C2 - 14571419

AN - SCOPUS:0142030701

VL - 30

SP - 717

EP - 723

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -